<DOC>
	<DOCNO>NCT01382797</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability efficacy ALKS 37 administer daily 4 week adults Opioid-induced Constipation ( OIC ) .</brief_summary>
	<brief_title>ALK37-005 : A Study ALKS 37 ( RDC-1036 ) Adults With Opioid-induced Constipation ( OIC )</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<criteria>Are least 18 year age time consent Have body mass index ( BMI ) 19 35 kg/m2 screening Are receive prescribed opioid medication management chronic , noncancer pain Meet criterion OIC Agree use acceptable method contraception duration study Pregnancy and/or currently breastfeed Clinically significant medical condition illness ( condition pain medication prescribe ) Receiving treatment opioid therapy cancerrelated pain , abdominal pain , scleroderma , and/or management drug addiction Any gastrointestinal ( GI ) disorder ( opioidinduced constipation ) GI structural abnormality know affect bowel transit , produce GI obstruction , contribute bowel dysfunction Use naloxone , Subutex Suboxone , Revia , Relistor , Entereg start 15 day first study visit follow screen end study Participation clinical trial pharmacological agent within 30 day screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>